Oral cholesterol-lowering therapies: The basis of prevention
Lale Tokgözoğlu, MD
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Roxana Mehran, MD
Exploring the role of a novel CETP inhibitor in lipid management
New insights on CETP inhibition from genetic research and clinical trials
Unmet needs in lowering LDL-c
Reassessing the role of triglycerides in residual cardiovascular risk
Richard Hobbs, MD
Integrating icosapent ethyl in preventive strategies: Practical guidance
Victor Aboyans, MD, PhD
The benefits of icosapent ethyl in addressing residual risk: What is the evidence?
New paradigms in the prevention of ASCVD: The role of EPA and triglycerides
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.